The Cancer Letter

Inside information on cancer research and drug development

Vol.
26
No.
1
January 31, 2003Jan 31, 2003
Free
DOWNLOAD THE PDF

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

FDA Approves Gleevec For First Line Rx Of CML

Fragmin Cuts Risk Of VE By 50 Percent In Study

Sirolimus-Containing Therapy Reduces GVHD, Study Finds

Avastin Regimen Bested Chemo Alone In Early Disease

Paraplatin Lengthened TTP In HER2+ Advanced Breast Ca

Study Confirms Cancer Risk Increase Due To Combined HRT

Pill Associated With Cancer In BRCA1 Mutation Carriers

National Cancer Institute Lists Approved Clinical Trials

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account